Francisco José López Jaime, MD

Hematologist
Hemostasis and Thrombosis Unit, Regional University Hospital of Málaga, IBIMA, Málaga, Spain.
Málaga, Andalucia, Spain

Francisco J. López Jaime, MD, works at University Hospital Regional of Málaga (Spain).
He is a specialist in Hemostasis and Thrombosis.
He participates as principal investigator in more than 20 clinical trials, including gene therapy and non-replacement drugs for hemophilia patients, such as emicizumab, concizumab or MIM8.
He actively participates in training for patients and families.

Presentation(s):

• PB0059 - Thrombomodulin resistance as a novel pathway involved in the hypercoagulable state of COVID-19 patients

  Sunday, June 25, 2023
  18:30 – 19:30 ET

• PB0220 - Clinical presentation and bleeding severity in women with autosomal inherited bleeding disorders and hemophilia carriers: real-life data from the Spanish Registry

  Sunday, June 25, 2023
  18:30 – 19:30 ET

• PB0684 - Quality of life in patients & caregivers living with hemophilia A without inhibitors in spain, interim analysis of the HEMOLIFE study

  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB1275 - Multicenter and cross-sectional study of joint damage of patients with non-severe hemophilia: A "Mediterranean Group" study

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1290 - Successful very low dose immune tolerance induction with albutrepenonacog alfa in a severe hemophilia B child with anaphylactic reaction to factor IX

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1294 - FIRST REPORTED CASE OF CARDIAC SURGERY IN A PATIENT WITH HEMOPHILIA B ON TREATMENT WITH ALBUTREPENONACOG ALFA (rIX-FP).

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1326 - Real-world data on correlation between emicizumab plasma levels, ex-vivo procoagulant profile and spontaneous joint annualized bleeding rate of patients on emicizumab prophylaxis

  Tuesday, June 27, 2023
  18:30 – 19:30 ET